LionEye Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

LionEye Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,381,000	Closed	-$48M	–	53
2015 Q2	$48M	Sell	1,381,000 -501,000	-27%	-$15.3M	1.86%	14
2015 Q1	$48.9M	Buy	+1,882,000	New	+$34.5M	1.97%	10

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LionEye Capital Management's HZNP Position: Q3 2015 in Review

LionEye Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 1,381,000 shares — an estimated $48M sold.

LionEye Capital Management first reported a position in HZNP in Q1 2015 and held it in 2 quarters. The position peaked at $48.9M in Q1 2015. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

LionEye Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
LionEye Capital Management sold 1,381,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $48M.
LionEye Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 2 quarters.
LionEye Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $48.9M in Q1 2015.
223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on LionEye Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.